Eleva has selected CDMO 3PBIOVAN to assist it with the manufacturing of its current biologics pipeline.
Under the terms of the agreement, Eleva will utilise 3PBIOVAN's production capacity to make the clinical-grade materials necessary for the advancement of the company's current clinical pipeline into late-stage development.
Notably, through this partnership, Eleva will nearly triple its GMP production capacity, enabling it to better explore the potential of its lead candidate, Factor H.
Factor H (CPV-104) is a recombinant complement modulator which is being designed for the treatment of both C3 glomerulopathy and dry age-related macular degeneration (AMD).
By signing with Eleva, 3PBIOVAN will also gain access to a non-exclusive license to Eleva's expression system.
CSO and Managing Director of Eleva, Dr Andreas Schaaf, commented: “With 3PBIOVIAN, we have secured a renowned and high-quality manufacturing partner to support our pipeline expansion strategy. As our current programs advance towards and through clinical studies, forward-looking planning of production capacity is a crucial success factor,”
“At the same time, a range of therapeutic opportunities in our industry could benefit immensely from our moss-based expression system. The relationship with 3PBIOVIAN will allow us to increase the visibility and market penetration of our platform and offers an integrated solution to advance new programs swiftly towards clinical development.”
Dámaso Molero Sánchez, Group CEO at 3PBIOVIAN, added: “We are delighted that Eleva has selected us as a partner for the manufacturing of clinical material for their current pipeline programs, including their novel complement regulator Factor H (CPV-104), which could provide patients with a much-needed new therapeutic option."
"Access to Eleva’s expression system also supports our commitment to meet the evolving needs of biopharmaceutical developers by continuously expanding our capabilities. Moss-based expression adds a valuable new dimension to our established high-quality offerings in biologics manufacturing.”
3PBIOVAN will also be responsible for the manufacture of any future programmes initiated by Eleva.